Video
Conference Coverage
Nothing to gain from chemo after pCR achieved
SAN ANTONIO - The only thing women with localized breast cancer who achieve a pCR after neoadjuvant chemo may gain from further chemo from...
Conference Coverage
Small absolute difference between partial and whole breast irradiation
SAN ANTONIO – A phase 3 trial was unable to rule out the possibility that, after lumpectomy, partial breast irradiation is inferior to whole...
Conference Coverage
LCAR-B38M CAR T therapy appears durable in myeloma
SAN DIEGO – Positive phase 1 results keep LCAR-B38M in the CAR T race in multiple myeloma.
Conference Coverage
No boost in OS with addition of capecitabine for early TNBC
SAN ANTONIO – Adding adjuvant capecitabine to surgery and standard chemotherapy did not improve disease-free or overall survival in women with...
Conference Coverage
2018: A banner year for hematology drug approvals
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
Conference Coverage
KATHERINE: T-DM1 doubles HER2-positive invasive disease-free survival
SAN ANTONIO – For the primary endpoint of invasive disease-free survival, T-DM1 was associated with a hazard ratio of 0.50.
Video
FLT3 inhibitor moves forward in newly diagnosed AML
SAN DIEGO – Dr. Keith W. Pratz reviewed results from a phase 1 study of gilteritinib and next steps in newly diagnosed patients.
Conference Coverage
DOAC pause yields favorable outcomes for AF patients
SAN DIEGO – Results from the PAUSE study could set the standard for timing of perioperative DOAC interruption.
Video
Sickle cell disease guidelines release set for early 2019
SAN DIEGO – Five new ASH guidelines for sickle cell disease are on the way, likely early in 2019.
